$AEON
AEON Biopharma, Inc.

2024 Q4 Form 10-Q Financial Statement

#000183760724000093 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.044M
YoY Change -44.25%
% of Gross Profit
Research & Development $972.0K
YoY Change -84.77%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.016M
YoY Change -106.94%
Operating Profit -$4.016M
YoY Change -106.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.155M
YoY Change -84.6%
Pretax Income -$6.171M
YoY Change -114.06%
Income Tax
% Of Pretax Income
Net Earnings -$6.171M
YoY Change -114.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 39.97M 39.52M
Diluted Shares Outstanding 39.52M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $500.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.371M
YoY Change -85.98%
LONG-TERM ASSETS
Property, Plant & Equipment $258.0K
YoY Change -27.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.00K
YoY Change 0.0%
Total Long-Term Assets $1.633M
YoY Change 130.65%
TOTAL ASSETS
Total Short-Term Assets $2.371M
Total Long-Term Assets $1.633M
Total Assets $4.004M
YoY Change -77.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.630M
YoY Change 15.38%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.73M
YoY Change -24.34%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.73M
Total Long-Term Liabilities
Total Liabilities $36.09M
YoY Change -74.1%
SHAREHOLDERS EQUITY
Retained Earnings -$433.7M
YoY Change 2.51%
Common Stock $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity
YoY Change
Total Liabilities & Shareholders Equity $4.004M
YoY Change -77.27%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$6.171M
YoY Change -114.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2023Q2 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q3 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q3 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
dei Entity Central Index Key
EntityCentralIndexKey
0001837607
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37159600
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39587630
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39587630
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40021
dei Entity Registrant Name
EntityRegistrantName
AEON Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3940478
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Park Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1750
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92614
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
354-6499
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Class A common stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
AEON
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39970693
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
537000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5158000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1834000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1064000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2371000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6222000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
258000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
332000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1346000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
262000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2024Q3 us-gaap Assets
Assets
4004000
CY2023Q4 us-gaap Assets
Assets
6845000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4630000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3388000
CY2024Q3 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
1373000
CY2023Q4 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
5128000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1563000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
943000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3160000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3590000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10726000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13049000
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
15170000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1204000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1844000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1447000
CY2024Q3 aeon Contingent Consideration Liability
ContingentConsiderationLiability
6886000
CY2023Q4 aeon Contingent Consideration Liability
ContingentConsiderationLiability
104350000
CY2024Q3 aeon Forward Purchase Agreement And Derivative Liability
ForwardPurchaseAgreementAndDerivativeLiability
264000
CY2023Q4 aeon Forward Purchase Agreement And Derivative Liability
ForwardPurchaseAgreementAndDerivativeLiability
41043000
CY2024Q3 us-gaap Liabilities
Liabilities
36094000
CY2023Q4 us-gaap Liabilities
Liabilities
159889000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39587630
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37159600
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
401585000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
381264000
CY2023Q4 aeon Subscription Receivables
SubscriptionReceivables
-60710000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433679000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-473602000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32090000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-153044000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4004000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6845000
CY2024Q3 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
CY2023Q3 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
CY2023Q3 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Predecessor
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
CY2023Q3 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Predecessor
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3044000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5265000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1055000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11014000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5265000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9841000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
972000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6388000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1573000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11144000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6388000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19803000
CY2023Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
348000000
CY2023Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
348000000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-75939000
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-97464000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-75939000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4016000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
283714000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2628000
us-gaap Operating Expenses
OperatingExpenses
-75306000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
283714000
us-gaap Operating Expenses
OperatingExpenses
29644000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4016000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-283714000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2628000
us-gaap Operating Income Loss
OperatingIncomeLoss
75306000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-283714000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29644000
CY2024Q3 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-1878000
CY2023Q3 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-13249000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-170000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-19359000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
377000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15376000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
CY2024Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
-81000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
11789000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
19931000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
11789000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
186000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
94000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
186000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2155000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13997000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25033000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35383000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13997000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31034000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6171000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-297711000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27661000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
39923000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-297711000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60678000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6171000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-297711000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-27661000
us-gaap Net Income Loss
NetIncomeLoss
39923000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-297711000
us-gaap Net Income Loss
NetIncomeLoss
-60678000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39515292
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38545882
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39515292
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41318831
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-27947000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6171000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
384000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1594000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32090000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
167144000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-297711000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2171000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-128396000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-283889000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-27661000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
730000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-310820000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-153044000
us-gaap Net Income Loss
NetIncomeLoss
39923000
aeon Termination Of Forward Purchase Agreements
TerminationOfForwardPurchaseAgreements
60710000
aeon Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
14979000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
384000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4908000
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32090000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
167144000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-297711000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2171000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-128396000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
us-gaap Net Income Loss
NetIncomeLoss
-60678000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3235000
aeon Stockholders Equity Period Increase Decrease Through Debit Extinguishment Due To Warrant Modification
StockholdersEquityPeriodIncreaseDecreaseThroughDebitExtinguishmentDueToWarrantModification
17036000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-310820000
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
CY2023Q3 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Predecessor
us-gaap Profit Loss
ProfitLoss
39923000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-297711000
us-gaap Profit Loss
ProfitLoss
-60678000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Share Based Compensation
ShareBasedCompensation
4908000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2171000
us-gaap Share Based Compensation
ShareBasedCompensation
3235000
CY2023Q3 aeon Inprocess Research And Development Expense Written Off
InprocessResearchAndDevelopmentExpenseWrittenOff
348000000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-170000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-19359000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
15376000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
19931000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
11789000
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-97464000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-75939000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
770000
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
363000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1242000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3716000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-3181000
CY2023Q3 aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-1701000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
4736000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-120000
CY2023Q3 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
6000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
28000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19671000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15061000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21745000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
15000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15050000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4621000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15061000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7745000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5158000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
537000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
500000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities and convertible notes. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., LTD. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitments_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
244000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
170000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
258000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
332000
us-gaap Legal Fees
LegalFees
1779000
CY2023 us-gaap Legal Fees
LegalFees
1867000
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
569000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
569000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278000
CY2024Q3 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
444000
CY2023Q4 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
33000
CY2024Q3 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
240000
CY2023Q4 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
843000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3160000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3590000
us-gaap Net Income Loss
NetIncomeLoss
-60678000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-27661000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-297711000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.01
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6171000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39515292
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39515292
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Net Income Loss
NetIncomeLoss
39923000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38545882
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41318831
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32405914
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29632965
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
CY2023Q3 aeon Number Of Shares To Be Received Prior To Merger
NumberOfSharesToBeReceivedPriorToMerger
2.328
CY2024Q3 aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
1900000
aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
200000
aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
19400000
CY2023Q3 aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
13200000
CY2024Q3 us-gaap Convertible Debt
ConvertibleDebt
15000000.0
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
0
CY2024Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
15200000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
0
CY2024Q3 aeon Subscription Receivable And Derivative Liability
SubscriptionReceivableAndDerivativeLiability
0
aeon Subscription Receivable And Derivative Liability
SubscriptionReceivableAndDerivativeLiability
20300000
CY2023Q2 aeon Number Of Additional Shares To Be Issued
NumberOfAdditionalSharesToBeIssued
16000000
CY2023Q2 aeon Threshold Increase In Episodic Migraine Contingent Consideration Shares
ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
11000000
CY2023Q2 aeon Number Of Chronic Migraine Contingent Consideration Shares By Increase In Episodic Migraine Contingent Consideration Shares
NumberOfChronicMigraineContingentConsiderationSharesByIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares
NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares
ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares
1000000
CY2023Q2 aeon Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction
MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction
0
CY2024Q3 aeon Contingent Consideration Liability
ContingentConsiderationLiability
6900000
CY2023Q4 aeon Contingent Consideration Liability
ContingentConsiderationLiability
104400000
CY2024Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
0
aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-97500000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-75900000
CY2024Q1 aeon Class Of Warrant Or Right Redemption Price
ClassOfWarrantOrRightRedemptionPrice
0.10
CY2024Q3 aeon Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
aeon Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1962638
CY2024Q3 aeon Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants
0
aeon Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants
15000000.0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
14479999
aeon Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
-10283637
aeon Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
-207410
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3988952
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
80000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
175000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
297000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
307000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
318000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
328000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1505000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
173000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1332000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1204000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1346000
CY2024Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5Y3M18D
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.043
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
72000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
53000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
16000
us-gaap Operating Lease Cost
OperatingLeaseCost
188000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
53000
us-gaap Operating Lease Cost
OperatingLeaseCost
153000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
80000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
26000
us-gaap Operating Lease Payments
OperatingLeasePayments
239000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
us-gaap Operating Lease Payments
OperatingLeasePayments
180000
CY2023Q3 aeon Deferred Underwriting Fee
DeferredUnderwritingFee
1250000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39587630
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30814688
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
38876675
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3200000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.041
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001837607-24-000093-index-headers.html Edgar Link pending
0001837607-24-000093-index.html Edgar Link pending
0001837607-24-000093.txt Edgar Link pending
0001837607-24-000093-xbrl.zip Edgar Link pending
aeon-20240930.xsd Edgar Link pending
aeon-20240930x10q.htm Edgar Link pending
aeon-20240930xex31.htm Edgar Link pending
aeon-20240930xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
aeon-20240930_cal.xml Edgar Link unprocessable
aeon-20240930_def.xml Edgar Link unprocessable
aeon-20240930_lab.xml Edgar Link unprocessable
aeon-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001837607-24-000093-index-headers.html Edgar Link pending
0001837607-24-000093-index.html Edgar Link pending
0001837607-24-000093.txt Edgar Link pending
0001837607-24-000093-xbrl.zip Edgar Link pending
aeon-20240930.xsd Edgar Link pending
aeon-20240930x10q.htm Edgar Link pending
aeon-20240930xex31.htm Edgar Link pending
aeon-20240930xex32.htm Edgar Link pending
aeon-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aeon-20240930x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aeon-20240930x10q_htm.xml Edgar Link completed
aeon-20240930_cal.xml Edgar Link unprocessable
aeon-20240930_def.xml Edgar Link unprocessable
aeon-20240930_lab.xml Edgar Link unprocessable